- Reported transaction lines
- 5
- Buy lines
- 0
- Sell lines
- 3
Filing activity by month
Original filing lines in up to 12 months with activity.
- 2026-115
Frequently disclosed stocks
Disclosure history
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source |
|---|---|---|---|---|---|---|
| JEAN CHRISTOPHE Director · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise or conversionFiling detailsSEC transaction code M Stock Options (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 0 · The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2026. · The options fully vested upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders. | 2026-11-17 | 2026-11-18 | 10,000 shares/units | SEC 4 |
| JEAN CHRISTOPHE Director · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 11712 · SEC code covers open-market or private transactions · The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2026. | 2026-11-17 | 2026-11-18 | ≈ $287,500.00 2,500 shares/units | SEC 4 |
| JEAN CHRISTOPHE Director · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 14212 · SEC code covers open-market or private transactions · The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2026. | 2026-11-17 | 2026-11-18 | ≈ $275,000.00 2,500 shares/units | SEC 4 |
| JEAN CHRISTOPHE Director · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 16712 · SEC code covers open-market or private transactions · The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2026. | 2026-11-17 | 2026-11-18 | ≈ $534,050.00 5,000 shares/units | SEC 4 |
| JEAN CHRISTOPHE Director · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 21712 · The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2026. | 2026-11-17 | 2026-11-18 | 10,000 shares/units | SEC 4 |
Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.